BeiGene, Ltd. (NASDAQ:BGNE) Shares Acquired by Sei Investments Co.

Sei Investments Co. boosted its holdings in BeiGene, Ltd. (NASDAQ:BGNE) by 3.6% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 24,248 shares of the company’s stock after acquiring an additional 848 shares during the quarter. Sei Investments Co.’s holdings in BeiGene were worth $3,459,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the business. Dimensional Fund Advisors LP boosted its position in shares of BeiGene by 118.9% during the 2nd quarter. Dimensional Fund Advisors LP now owns 11,499 shares of the company’s stock valued at $1,649,000 after purchasing an additional 6,246 shares in the last quarter. Oppenheimer Asset Management Inc. boosted its holdings in BeiGene by 48.6% during the second quarter. Oppenheimer Asset Management Inc. now owns 26,924 shares of the company’s stock worth $3,841,000 after buying an additional 8,800 shares in the last quarter. Barings LLC grew its position in BeiGene by 66.4% in the second quarter. Barings LLC now owns 51,763 shares of the company’s stock worth $7,385,000 after buying an additional 20,663 shares during the last quarter. Headlands Technologies LLC increased its holdings in shares of BeiGene by 761.2% in the second quarter. Headlands Technologies LLC now owns 2,773 shares of the company’s stock valued at $396,000 after buying an additional 2,451 shares in the last quarter. Finally, TD Asset Management Inc lifted its position in shares of BeiGene by 1.4% during the 2nd quarter. TD Asset Management Inc now owns 114,378 shares of the company’s stock valued at $16,318,000 after acquiring an additional 1,599 shares during the last quarter. 48.55% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages recently weighed in on BGNE. Bank of America dropped their price target on BeiGene from $180.00 to $152.50 and set a “neutral” rating on the stock in a research note on Tuesday, July 9th. Citigroup lifted their price objective on shares of BeiGene from $269.00 to $288.00 and gave the stock a “buy” rating in a research report on Thursday, August 8th. JPMorgan Chase & Co. increased their target price on BeiGene from $194.00 to $200.00 and gave the company an “overweight” rating in a report on Tuesday, August 20th. Finally, JMP Securities initiated coverage on BeiGene in a report on Wednesday, September 18th. They set a “market outperform” rating and a $288.00 price target on the stock. Three investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $241.21.

BeiGene Stock Up 1.1 %

NASDAQ BGNE opened at $233.60 on Thursday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.75 and a current ratio of 1.98. BeiGene, Ltd. has a 52 week low of $126.97 and a 52 week high of $238.80. The stock has a market capitalization of $22.64 billion, a P/E ratio of -30.86 and a beta of 0.61. The stock has a fifty day moving average of $190.73 and a 200-day moving average of $166.90.

BeiGene (NASDAQ:BGNE) last issued its earnings results on Wednesday, August 7th. The company reported ($1.15) EPS for the quarter, beating the consensus estimate of ($2.27) by $1.12. The firm had revenue of $929.20 million during the quarter, compared to the consensus estimate of $810.34 million. BeiGene had a negative net margin of 16.91% and a negative return on equity of 14.93%. The business’s quarterly revenue was up 56.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($3.64) earnings per share. On average, equities research analysts forecast that BeiGene, Ltd. will post -5.13 EPS for the current year.

Insider Buying and Selling

In other news, SVP Chan Henry Lee sold 834 shares of the business’s stock in a transaction dated Tuesday, July 30th. The shares were sold at an average price of $160.57, for a total value of $133,915.38. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, insider Titus B. Ball sold 137 shares of the company’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $189.94, for a total value of $26,021.78. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, SVP Chan Henry Lee sold 834 shares of BeiGene stock in a transaction on Tuesday, July 30th. The shares were sold at an average price of $160.57, for a total transaction of $133,915.38. The disclosure for this sale can be found here. Over the last three months, insiders have sold 17,729 shares of company stock worth $3,601,007. Insiders own 7.43% of the company’s stock.

About BeiGene

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.